XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Summary

This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). XL092 is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing.

Conditions

• Locally Advanced Differentiated Thyroid Gland Carcinoma
• Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
• Locally Advanced Thyroid Gland Follicular Carcinoma
• Locally Advanced Thyroid Gland Oncocytic Carcinoma
• Locally Advanced Thyroid Gland Papillary Carcinoma
• Metastatic Differentiated Thyroid Gland Carcinoma
• Metastatic Poorly Differentiated Thyroid Gland Carcinoma
• Metastatic Thyroid Gland Follicular Carcinoma
• Metastatic Thyroid Gland Oncocytic Carcinoma
• Metastatic Thyroid Gland Papillary Carcinoma
• Refractory Differentiated Thyroid Gland Carcinoma
• Refractory Poorly Differentiated Thyroid Gland Carcinoma
• Refractory Thyroid Gland Follicular Carcinoma
• Refractory Thyroid Gland Oncocytic Carcinoma
• Refractory Thyroid Gland Papillary Carcinoma
• Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
• Stage III Thyroid Gland Follicular Carcinoma AJCC v8
• Stage III Thyroid Gland Papillary Carcinoma AJCC v8
• Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
• Stage IV Thyroid Gland Follicular Carcinoma AJCC v8
• Stage IV Thyroid Gland Papillary Carcinoma AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Survey Administration

Ancillary studies

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

DRUG

Zanzalintinib

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Northwestern University

  lead OTHER

Principal Investigators

• Jochen H Lorch · Northwestern University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-06-06

Primary Completion

2028-09-11

Completion

2030-09-11

FDA Drug

Yes

Countries

• United States

Study Locations